Clinical trials: Prostate Cancer (CRPC)
Prostate Cancer
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue).
- Trial name
- NCT01558492
- Testing
- Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT06801236
- Testing
- ACE-232 tablets
- Where
- 13 sites in United States, China
- Volunteers
- 88 people
- Sponsor
- Acerand Therapeutics (Hong Kong) Limited
Castrate-Resistant Prostate Cancer
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
- Trial name
- NCT01234025
- Testing
- ISIS EIF4E Rx, Prednisone, Docetaxel
- Where
- 38 sites in United States, Hungary and 4 more
- Volunteers
- 113 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Prostate Cancer
18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer
Evaluate the ability of 18F-FCH PET/MRI scan to detect pre-treatment tumor burden and assess response to treatment in men with castration resistant prostate cancer (CRPC).
- Trial name
- NCT02121600
- Testing
- [F-18]-FCH, PET scan, MRI scan
- Where
- 3 sites in Canada
- Volunteers
- 5 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): efficacy and toxicity evaluation
- Trial name
- LU-PSMA (NCT03454750)
- Testing
- 177Lu-PSMA
- Where
- Italy
- Volunteers
- 143 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
- Trial name
- ARMOR1 (NCT00959959)
- Testing
- TOK-001
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate…
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02012296
- Testing
- enzalutamide, mifepristone, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- University of Chicago
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01270880
- Testing
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostatic Cancer, Castration-Resistant
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking…
- Trial name
- PEACE8 (NCT06276465)
- Testing
- Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy
- Where
- 4 sites in France
- Volunteers
- 336 people
- Sponsor
- UNICANCER
Prostate Cancer
Efficacy Study of ABR-215050 to Treat Prostate Cancer
To investigate ABR-215050 as a possible treatment for prostate cancer.
- Trial name
- NCT00560482
- Testing
- ABR-215050, tasquinimod
- Where
- 65 sites in United States, Canada and 1 more
- Volunteers
- 206 people
- Sponsor
- Active Biotech AB
Hormone Refractory Prostate Cancer
Molecular Phenotype Changes and Personalized Treatment for CRPC
To explore the molecular phenotypic changes and personalized treatment in castration-resistant prostate cancer.
- Trial name
- NCT02208583
- Testing
- Docetaxel & Prednisone, DP & Targeted drugs, cisplatin & Etoposide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Prostate Cancer (CRPC)
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen…
- Trial name
- NCT07871110
- Testing
- tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide
- Where
- 16 sites in China
- Volunteers
- 182 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Diarrhea, Hormone-resistant Prostate Cancer
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel.
- Conditions
- Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT01469338
- Testing
- cabazitaxel, prednisone, octreotide pamoate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Southern California
Prostate Cancer, Prostate Neoplasms
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
This study is to evaluate safety, tolerability pharmacokinetics and efficacy of MDV3100 after oral administration to patients with castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Neoplasms, Castration Resistant Prostate Cancer (CRPC)
- Trial name
- NCT01284920
- Testing
- MDV3100
- Where
- 7 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer Metastatic, Prostate Cancer
Castrate Resistant Prostate Cancer Enhertu Therapy
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer, CRPC
- Trial name
- CaRPET (NCT06610825)
- Testing
- Enhertu
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington D.C. Veterans Affairs Medical Center
Solid Tumor Cancer, Castration Resistant Prostate Cancer
Imaging of Solid Tumors Using DLL3 SPECT
This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors.
- Conditions
- Solid Tumor Cancer, Castration Resistant Prostate Cancer, Castration Resistant Prostate Cancer (CRPC), Neuroendocrine (NE) Tumors
- Trial name
- NCT07052760
- Testing
- 111In-ABD147, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
- Sponsor
- Thomas Hope
Prostate Cancer
Abiraterone-Rechallenge Study for CRPC Patients
To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.
- Trial name
- ABI-RE (NCT02656615)
- Testing
- abiraterone acetate
- Where
- 3 sites in Switzerland
- Volunteers
- 4 people
- Sponsor
- Aurelius Omlin
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.